Andere talen CanSino Biologics Inc.

Aandelen

6185

CNE100003F01

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,82 ^HKD	+2,51%		+14,06%	-20,08%

21/03	Cansino Biologics start met fase III klinische studies voor tetanusvaccin	MT
20/03	Cansino Biologics Inc. Kondigt de start aan van fase III klinische studie en de voltooiing van de eerste proefpatiënt voor het geabsorbeerde tetanusvaccin	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	26/04
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	22/04
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	22/04
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough	27/03
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia	25/03
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	14/03
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02
Cansino Biologics Inc. Announces Board and Committee Elections	23/02
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
CanSino Biologics Deconsolidates CanSino SPH	02/02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31/01
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01
CanSino Biologics Enrols First Patient in Australia Clinical Trial of Polio Vaccine	15/01
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

CanSino Biologics over AstraZeneca-deal, inkomsten

31 augustus 2023 om 12:08 uur